tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MindBio Therapeutics Unveils Booze AI, A Revolutionary Blood Alcohol Estimator

Story Highlights
  • MindBio Therapeutics has completed the Booze AI software, an AI-powered blood alcohol estimator.
  • Booze AI aims to educate users on alcohol risks and deter drink driving with accurate BAC predictions.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
MindBio Therapeutics Unveils Booze AI, A Revolutionary Blood Alcohol Estimator

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has issued an update.

MindBio Therapeutics Corp. has announced the completion of its Booze AI software, a groundbreaking voice-activated, AI-powered blood alcohol estimator designed for smartphones and computers. This innovative tool, which stems from clinical trials using MindBio’s proprietary microdose formulation of LSD, aims to educate users about the risks of alcohol consumption and deter drink driving by providing accurate blood alcohol concentration predictions and performance impairment assessments.

More about Mindbio Therapeutics Corp.

MindBio Therapeutics Corp. is a clinical-stage biopharma/biotechnology company focused on developing novel and effective mental health treatments.

Average Trading Volume: 145,376

Technical Sentiment Signal: Sell

Find detailed analytics on MBIO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1